SBH
DNLI icon

Segall Bryant & Hamill’s Denali Therapeutics DNLI Stock Holding History

Segall Bryant & Hamill’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
519,483
+8,940
+2% +$184K 0.16% 211
2026
Q1 		$9.8M Sell
510,543
-26,457
-5% -$526K 0.14% 231
2025
Q4 		$8.87M Buy
537,000
+24,042
+5% +$406K 0.12% 246
2025
Q3 		$7.45M Buy
512,958
+12,399
+2% +$178K 0.1% 272
2025
Q2 		$7M Buy
500,559
+219,420
+78% +$3.09M 0.1% 278
2025
Q1 		$3.82M Sell
281,139
-7,936
-3% -$152K 0.06% 348
2024
Q4 		$5.89M Buy
+289,075
New +$7.4M 0.08% 304

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's DNLI Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Denali Therapeutics (DNLI) stake by 1.8% in Q2 2026, buying an estimated $184K and bringing the position to 519,483 shares worth $13.4M. The position accounts for 0.16% of the portfolio, ranked #211.

Segall Bryant & Hamill first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Segall Bryant & Hamill held 519,483 shares of Denali Therapeutics worth $13.4M as of Q2 2026.
  • Segall Bryant & Hamill bought 8,940 Denali Therapeutics shares in Q2 2026, an estimated $184K.
  • Denali Therapeutics made up 0.16% of Segall Bryant & Hamill's portfolio in Q2 2026, its #211 holding.
  • Segall Bryant & Hamill first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.